


€132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital?
Europe’s biotech ecosystem just notched a headline-grabbing win. Azafaros, a

A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters
